O’Melveny advised Vivo Capital as the leader of an investment syndicate in the investment syndicate’s definitive agreement to acquire Canadian medical device maker Angiotech Pharmaceuticals. Vivo…
Vivo Capital’s acquisition of Angiotech
O’Melveny advised Vivo Capital as the leader of an investment syndicate in the investment syndicate’s definitive agreement to acquire Canadian medical device maker Angiotech Pharmaceuticals. Vivo…